Showing results (481-490 of 911) with videos related to
Sort By:
Pageof 92
Journal of Oncology Practice|September 22, 2010
Targeting Lymph Node Retrieval and Assessment in Stage II Colon Cancer: A Quality Outcome Community-Based Cancer Center StudyThomas Grote, Amy H Hughes, Cathy C Rimmer, et al.Contraception|December 1, 1989
A study of the vaginal contraceptive sponge used with and without the fertility awareness methodB Kass-Annese, K I Kennedy, K Forrest, et al.The American Journal of Psychiatry|October 11, 1992
Resident physician substance use, by specialtyP H Hughes, D C Baldwin, D V Sheehan, et al.Plos Pathogens|February 18, 2006
Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?Paul L Boyer, Stefan G Sarafianos, Patrick K Clark, et al.Journal of Virology|February 14, 2006
The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudineZandrea Ambrose, John G Julias, Paul L Boyer, et al.The Journal of Biological Chemistry|March 25, 1981
Multiple alpha and beta tubulin genes represent unlinked and dispersed gene familiesD W Cleveland, S H Hughes, E Stubblefield, et al.Annals of the New York Academy of Sciences|January 1, 1980
The origin and structure of endogenous retroviral DNAH E Varmus, J C Cohen, S H Hughes, et al.Virology|July 17, 2007
In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RTPaul L Boyer, Carolyn R Stenbak, David Hoberman, et al.Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Protein delivery using engineered virus-like particlesStanislaw J Kaczmarczyk, Kalavathy Sitaraman, Howard A Young, et al.Chemical Biology & Drug Design|August 4, 2020
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutantsSteven J Smith, Gary T Pauly, Katharine Hewlett, et al.Pageof 92